卵巢癌患者癌组织MMP-10、IL-17A、HMGB1表达与病情严重程度的相关性

Correlation between MMP-10,IL-17A and HMGB1 in cancer tissues and disease severity in patients with ovarian cancer

目的:探究卵巢癌患者癌组织基质金属蛋白酶10(MMP-10)、白细胞介素17A(IL-17A)、高迁移率族蛋白B1(HMGB1)水平与病情严重程度相关性。方法:将407例卵巢癌患者的临床资料作为观察组,以同期就诊的216例良性卵巢肿瘤患者为对照组。检测并比较两组患者血清MMP-10、IL-17A、HMGB1水平,分析不同参数下卵巢癌患者血清MMP-10、IL-17A、HMGB1水平,利用Spearman分析卵巢癌患者血清MMP-10、IL-17A、HMGB1与FIGO分期、分化程度的相关性。结果:入院时,观察组患者血清MMP-10、IL-17A、HMGB1水平均高于对照组(P<0.05)。不同FIGO分期、分化程度、淋巴结转移卵巢癌患者中血清MMP-10、IL-17A、HMGB1水平有统计学差异(P<0.05)。Spearman分析显示血清MMP-10、IL-17A、HMGB1与FIGO分期、分化程度均呈正相关关系(P<0.05)。结论:血清MMP-10、IL-17A、HMGB1与FIGO分期、分化程度呈正相关,可作为卵巢癌患者病情严重程度的诊断指标。

Objective:To explore the correlation between levels of matrix metalloproteinase-10(MMP-10),interleukin-17A(IL-17A)and high mobility group protein B1(HMGB1)in cancer tissues and disease severity in patients with ovarian cancer.Methods:A retrospective analysis was performed on the clinical data of 407 patients with ovarian cancer(observation group)and 216 patients with benign ovarian tumors(control group).The levels of serum MMP-10,IL-17A and HMGB1 were detected at admission,and which were compared between the two groups.The levels of serum MMP-10,IL-17A and HMGB1 among ovarian cancer patients with different parameters were analyzed.The correlation between serum MMP-10,IL-17A,HMGB1 and FIGO staging,differentiation degree in patients with ovarian cancer was analyzed by Spearman analysis.Results:At admission,levels of serum MMP-10,IL-17A and HMGB1 in observation group were higher than those in control group(P<0.05).There were significant differences in levels of serum MMP-10,IL-17A and HMGB1 among patients with different FIGO staging,differentiation degree and lymph node metastases(P<0.05).Spearman analysis showed that levels of serum MMP-10,IL-17A and HMGB1 were positively correlated with FIGO staging and differentiation degree(P<0.05).Conclusion:Serum MMP-10,IL-17A and HMGB1 are positively correlated with FIGO staging and differentiation degree,which can be applied as diagnostic indexes for disease severity in patients with ovarian cancer.